Efficacy of SGLT2 inhibitors on acute kidney injury in patients with chronic kidney disease, cardiovascular disease, and type 2 diabetes: A meta-analysis
SGLT2 inhibitors significantly reduce the risk of AKI in patients with CKD, CVD, and T2DM, with greater efficacy observed in those with higher initial eGFR. However, when eGFR falls below 45 mL/min/1.73 m², SGLT2 inhibitors do not reduce the occurrence of AKI.
Authors
- Tingting Deng (ORCID: https://orcid.org/0000-0002-4937-624X)
- Lifang Hou (ORCID: https://orcid.org/0000-0003-4877-0031)
- Zhougui Ling
- Zhiyuan Dong
- Wenqing Mo (ORCID: https://orcid.org/0009-0000-2251-2806)
Institutions
- Fourth Affiliated Hospital of Guangxi Medical University (CN)
Publication Details
- Journal
- Journal of the National Medical Association
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1016/j.jnma.2025.08.110
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00